DFP-10917

CAS No. 135598-68-4

DFP-10917( CNDAC | TAS-109 )

Catalog No. M11458 CAS No. 135598-68-4

DFP-10917 (CNDAC, TAS-109) is a deoxycytidine analog with antitumor activity against various tumor cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    DFP-10917
  • Note
    Research use only, not for human use.
  • Brief Description
    DFP-10917 (CNDAC, TAS-109) is a deoxycytidine analog with antitumor activity against various tumor cells.
  • Description
    DFP-10917 (CNDAC, TAS-109) is a deoxycytidine analog with antitumor activity against various tumor cells; is an orally available nucleoside analog prodrug of CNDAC, CNDAC (DFP-10917) is phosphorylated to generate its nucleotide form, functioning as a deoxycytosine mimic and is incorporated into DNA in tumor cells, causes DNA strand breaks during polymerization due to beta-elimination during the fidelity checkpoint, resulting in G2/M phase-arrest and tumor cell apoptosis.Blood Cancer Phase 2 Clinical.
  • In Vitro
    Cell Viability Assay Cell Line:Rad51D-deficient 51D1, Rad51D-complemented 51D1.3, wild-type AA8 and XRCC3-deficient irs1SF CHO cellsConcentration:0-1 μMIncubation Time:24 hResult:Inhibited cell survival with IC50s of 0.006, 0.32, 0.48 and 0.0053 μM against Rad51D-deficient 51D1, Rad51D-complemented 51D1.3, wild-type AA8 and XRCC3-deficient irs1SF cell lines, respectively.Cell Proliferation Assay Cell Line:HL-60 and THP-1 cells Concentration:0-100 μM Incubation Time:3 days Result:Inhibited proliferation with IC50s of 1.5832 μM and 0.84 μM against HL-60 and THP-1 cells, respectively.Apoptosis Analysis Cell Line:HL-60 and THP-1 cells Concentration:0, 0.5, 1, 2, 3, 4, 5 and 10 μM Incubation Time:3, 4, 5, and 6 days Result:Induced apoptosis in both cells.Cell Cycle Analysis Cell Line:HCT116 Concentration:6?μM Incubation Time:48?h Result:36 and 36% of cells were arrested in late-S and G2/M phases, respectively.
  • In Vivo
    Animal Model:CDF1 mice, P388 tumor modelDosage:20 mg/kg Administration:Intraperitoneal injection, daily for 10 daysResult:Greatly increased the survival time and survival rate.
  • Synonyms
    CNDAC | TAS-109
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Nucleoside Antimetabolite/Analog
  • Recptor
    Nucleoside Antimetabolite/Analog
  • Research Area
    Cancer
  • Indication
    Blood cancer

Chemical Information

  • CAS Number
    135598-68-4
  • Formula Weight
    252.23
  • Molecular Formula
    C10H12N4O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N#C[C@@H]1[C@H](N2C=CC(N)=NC2=O)O[C@H](CO)[C@H]1O
  • Chemical Name
    (2R,3S,4S,5R)-2-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-3-carbonitrile

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Matsuda A, et al. J Med Chem. 1991 Sep;34(9):2917-9. 2. Sankhala K, et al. Invest New Drugs. 2018 Apr 18. doi: 10.1007/s10637-018-0602-0. 3. Hanaoka K, et al. Int J Cancer. 1999 Jul 19;82(2):226-36. 4. Tanaka M, et al. Cancer Lett. 1992 May 30;64(1):67-74.
molnova catalog
related products
  • Tipiracil hydrochlor...

    Tipiralacil, also known as TPI, is a thymidine phosphorylase inhibitor (TPI).

  • Elacytarabine

    Elacytarabine (CP-4055, CP4055, ELACYT) is a fatty acid derivative of cytarabine with potential antineoplastic activity.

  • Acelarin

    A gemcitabine phosphoramidate prodrug that can overcome the key cancer resistance.